DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Edmonds Duncan Registered Investment Advisors LLC

Edmonds Duncan Registered Investment Advisors LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 25.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,870 shares of the medical device company’s stock after selling 626 shares during the period. Edmonds Duncan Registered Investment Advisors LLC’s holdings in DexCom were worth $259,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. DSM Capital Partners LLC purchased a new stake in DexCom during the fourth quarter valued at about $28,000. Valley National Advisers Inc. increased its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co purchased a new position in DexCom in the first quarter valued at about $32,000. MV Capital Management Inc. lifted its stake in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Smithfield Trust Co boosted its position in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $0.46 during trading hours on Tuesday, hitting $111.71. The stock had a trading volume of 374,887 shares, compared to its average volume of 2,937,115. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a market capitalization of $44.42 billion, a price-to-earnings ratio of 72.29, a PEG ratio of 2.77 and a beta of 1.16. The stock’s fifty day simple moving average is $122.75 and its 200 day simple moving average is $125.65. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Sell-side analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of several analyst reports. Raymond James raised their target price on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Canaccord Genuity Group lifted their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Citigroup upped their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $140.33.

Insider Activity

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the transaction, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The disclosure for this sale can be found here. Insiders sold 55,735 shares of company stock worth $7,619,347 over the last three months. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.